Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2Ag.S |
Molecular Weight | 247.801 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[S--].[Ag+].[Ag+]
InChI
InChIKey=XUARKZBEFFVFRG-UHFFFAOYSA-N
InChI=1S/2Ag.S/q2*+1;-2
Molecular Formula | Ag |
Molecular Weight | 107.8682 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HS |
Molecular Weight | 33.073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26897901https://www.ncbi.nlm.nih.gov/pubmed/25781988The legal airborne permissible exposure limit (PEL) is 11 mg/m^2 averaged over an 8-hour workshift.https://www.ncbi.nlm.nih.gov/pubmed/20429870https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2930 | https://www.ncbi.nlm.nih.gov/pubmed/11294738https://www.purebio.com/assets/001/5202.pdfhttp://google.com/patents/CN102923966Bhttps://www.ncbi.nlm.nih.gov/pubmed/19278981Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26687774 | https://clinicaltrials.gov/ct2/show/NCT01950546 | https://www.ncbi.nlm.nih.gov/pubmed/24373700
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26897901https://www.ncbi.nlm.nih.gov/pubmed/25781988The legal airborne permissible exposure limit (PEL) is 11 mg/m^2 averaged over an 8-hour workshift.https://www.ncbi.nlm.nih.gov/pubmed/20429870https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2930 | https://www.ncbi.nlm.nih.gov/pubmed/11294738https://www.purebio.com/assets/001/5202.pdfhttp://google.com/patents/CN102923966Bhttps://www.ncbi.nlm.nih.gov/pubmed/19278981
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26687774 | https://clinicaltrials.gov/ct2/show/NCT01950546 | https://www.ncbi.nlm.nih.gov/pubmed/24373700
Silver Fluoride is an odorless yellow to gray solid salt with the formula AgF. Silver Fluoride has relatively few niche applications; it has been employed as a fluorination and desilylation reagent in organic synthesis and in aqueous solution as a topical caries treatment in dentistry. Multiple studies have shown silver(I) fluoride to be an effective anti-caries agent. Treatment is typically by the "atraumatic" method, in which 40% by mass aqueous silver(I) fluoride solution is applied to carious lesions, followed by sealing of the dentine with glass ionomer cement. Although the treatment is generally recognized to be safe, fluoride toxicity has been a significant clinical concern in pediatric applications, especially as some commercial preparations have had considerable silver(II) fluoride contamination in the past. Due to the instability of concentrated AgF solutions, silver diamine fluoride (Ag(NH3)2F) is now more commonly used.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20429870Vestsi Akademii Navuk BSSR, Seryya Khimichnykh Navuk, Issue 2, Pages 69-73, Journal, 1990
Curator's Comment: The medical uses of silver date back to at least the time of Hippocrates
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232 |
|||
Target ID: GO:0034505 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26897901 |
|||
Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232 |
|||
Target ID: GO:0034505 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24373700 |
|||
Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232 |
|||
Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Advantage Arrest Silver Diamine Fluoride Approved UseUnknown |
|||
Primary | Advantage Arrest Silver Diamine Fluoride Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Primary | Colloidal silver iodide Approved UseSolution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose. |
|||
Primary | Colloidal silver iodide Approved UseSolution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose. |
|||
Palliative | Unknown Approved UseAntiseptic Wound Cauterization |
|||
Primary | Unknown Approved UseProphylaxis of gonococcal ophthalmia neonatorum. AAP recommends use of topical silver nitrate, povidone-iodine, or possibly erythromycin for prophylaxis of nongonococcal nonchlamydial conjunctivitis in neonates, ideally administered shortly after birth. |
PubMed
Title | Date | PubMed |
---|---|---|
Lack of genotoxicity of silver iodide in the SCE assay in vitro, in vivo, and in the Ames/microsome test. | 1998 |
|
A chemically intelligent antimicrobial coating for urologic devices. | 2000 Feb |
|
New disinfection and sterilization methods. | 2001 Mar-Apr |
|
Comparative efficacy of hand hygiene agents in the reduction of bacteria and viruses. | 2005 Mar |
|
Photocatalytic degradation of pathogenic bacteria with AgI/TiO2 under visible light irradiation. | 2007 Apr 24 |
|
Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. | 2008 Apr |
|
Topical antimicrobials for burn wound infections. | 2010 Jun |
|
Development of silica-coated silver iodide nanoparticles and their biodistribution. | 2012 Dec |
|
A novel silver iodide metalo-drug: experimental and computational modelling assessment of its interaction with intracellular DNA, lipoxygenase and glutathione. | 2014 Apr 22 |
|
UCSF Protocol for Caries Arrest Using Silver Diamine Fluoride: Rationale, Indications and Consent. | 2016 Jan |
|
An alternate technique of care using silver fluoride followed by stannous fluoride in the management of root caries in aged care. | 2016 Mar-Apr |
|
Directional growth of Ag nanorod from polymeric silver cyanide: A potential substrate for concentration dependent SERS signal enhancement leading to melamine detection. | 2017 Aug 5 |
|
The antifungal effects and mechanical properties of silver bromide/cationic polymer nano-composite-modified Poly-methyl methacrylate-based dental resin. | 2017 May 8 |
Sample Use Guides
For up to 5 treated sites per patient, dispense 1-2 drops of solution (Aqueous Silver Diamine Fluoride, 38.3% to 43.2% w/v) into a disposable dappen dish. Transfer material directly to the tooth surface with an applicator.
Route of Administration:
Dental
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 03:41:12 UTC 2022
by
admin
on
Sat Dec 17 03:41:12 UTC 2022
|
Record UNII |
9ZB10YHC1C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SILVER SULFIDE
Created by
admin on Sat Dec 17 03:41:12 UTC 2022 , Edited by admin on Sat Dec 17 03:41:12 UTC 2022
|
PRIMARY | |||
|
166738
Created by
admin on Sat Dec 17 03:41:12 UTC 2022 , Edited by admin on Sat Dec 17 03:41:12 UTC 2022
|
PRIMARY | |||
|
21548-73-2
Created by
admin on Sat Dec 17 03:41:12 UTC 2022 , Edited by admin on Sat Dec 17 03:41:12 UTC 2022
|
PRIMARY | |||
|
M9939
Created by
admin on Sat Dec 17 03:41:12 UTC 2022 , Edited by admin on Sat Dec 17 03:41:12 UTC 2022
|
PRIMARY | Merck Index | ||
|
9ZB10YHC1C
Created by
admin on Sat Dec 17 03:41:12 UTC 2022 , Edited by admin on Sat Dec 17 03:41:12 UTC 2022
|
PRIMARY | |||
|
9ZB10YHC1C
Created by
admin on Sat Dec 17 03:41:12 UTC 2022 , Edited by admin on Sat Dec 17 03:41:12 UTC 2022
|
PRIMARY | |||
|
1549110
Created by
admin on Sat Dec 17 03:41:12 UTC 2022 , Edited by admin on Sat Dec 17 03:41:12 UTC 2022
|
PRIMARY | RxNorm | ||
|
DTXSID80893679
Created by
admin on Sat Dec 17 03:41:12 UTC 2022 , Edited by admin on Sat Dec 17 03:41:12 UTC 2022
|
PRIMARY | |||
|
244-438-2
Created by
admin on Sat Dec 17 03:41:12 UTC 2022 , Edited by admin on Sat Dec 17 03:41:12 UTC 2022
|
PRIMARY | |||
|
C013251
Created by
admin on Sat Dec 17 03:41:12 UTC 2022 , Edited by admin on Sat Dec 17 03:41:12 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |